Skip to main content
Article thumbnail
Location of Repository

In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile

By Michael J Sorich, Nicolas Pottier, Deqing Pei, Wenjian Yang, Leo Kager, Gabriele Stocco, Cheng Cheng, John C Panetta, Ching-Hon Pui, Mary V Relling, Meyling H Cheok and William E Evans


William Evans and colleagues investigate the genomic determinants of methotrexate resistance and interpatient differences in methotrexate response in patients newly diagnosed with childhood acute lymphoblastic leukemia

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). A global test for groups of genes: testing association with a clinical outcome.
  2. (2006). A new mechanism of methotrexate action revealed by target screening with affinity beads.
  3. (1999). A proportional hazards model for the subdistribution of a competing risk.
  4. (2007). A set of genes that regulate cell proliferation predict treatment outcome in childhood acute lymphoblastic leukemia.
  5. (1990). Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis.
  6. (1996). Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
  7. (2006). Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
  8. (2004). Acute lymphoblastic leukemia.
  9. (2002). Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.
  10. (1999). Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.
  11. (2004). Bioconductor: open software development for computational biology and bioinformatics.
  12. (1990). Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia.
  13. (1994). Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.
  14. (2003). Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia.
  15. (2002). Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
  16. (2001). Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials.
  17. (2002). De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
  18. (1994). Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia.
  19. (1999). Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
  20. (2005). Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
  21. (1980). Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products.
  22. (2003). Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia.
  23. (2005). Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
  24. (2006). Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.
  25. (2004). Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
  26. (1999). High density synthetic oligonucleotide arrays.
  27. (2005). Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
  28. (1996). Intrinsic and acquired resistance to methotrexate in acute leukemia.
  29. (2000). Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children’s Research Hospital.
  30. (2003). Membrane transport of folates.
  31. (2002). Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity.
  32. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
  33. (2001). Multiclass cancer diagnosis using tumor gene expression signatures.
  34. (2002). Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
  35. (2005). Pharmacogenetics of outcomeinchildrenwithacutelymphoblasticleukemia.Blood105:4752–4758.
  36. (1985). Polyglutamation of methotrexate. Is methotrexate a prodrug?
  37. (1988). Proliferation-dependent cytotoxicity of methotrexate in murine L5178Y leukemia.
  38. (2004). Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia.
  39. (2003). Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children’s Cancer Group Study.
  40. (1996). Regulatory genes and drug sensitivity.
  41. (2004). Relling MV
  42. (2003). Results of therapy for acute lymphoblastic leukemia in black and white children.
  43. (2003). Statistical significance for genomewide studies.
  44. (2001). Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
  45. (2006). Treatment of acute lymphoblastic leukemia.
  46. (1996). Use of a cDNA microarray to analyse gene expression patterns in human cancer.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.